Vaccination in children with immune-mediated disorders

被引:1
|
作者
Marinho, Ana Karolina Barreto Berselli [1 ]
机构
[1] Univ Sao Paulo HCFMUSP, Hosp Clin, Fac Med, Serv Imunol Clin & Alergia, Sao Paulo, SP, Brazil
关键词
Children with immune-mediated rheumatic; inflamma-tory diseases; Live attenuated vaccines; Non-live" vaccines; Immunogenicity; Safety; JUVENILE IDIOPATHIC ARTHRITIS; PNEUMOCOCCAL CONJUGATE VACCINE; RHEUMATIC-DISEASES; PEDIATRIC-PATIENTS; VARICELLA VACCINE; IMMUNOGENICITY; SAFETY; TOLERABILITY; ADOLESCENTS; IMMUNIZATION;
D O I
10.1016/j.jped.2022.11.008
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To present an updated review of recommendations for the vaccination of children with immune-mediated diseases, with an emphasis on rheumatic and inflammatory diseases.Source of data: Studies published in the PubMed and Scielo databases between 2002 and 2022, Guidelines of Brazilian Scientific Societies, Manuals and Technical Notes of the Ministry of Health of Brazil, on current immunization schedules for special populations. Data synthesis: Immunosuppressive drugs and biological agents reduce the immunogenicity of vaccines and favor susceptibility to infections. The safety and efficacy of immunogens are impor-tant points for vaccination in children with immune-mediated diseases. The safety threshold of a vaccine applied to immunocompromised individuals can be reduced when compared to healthy individuals. Very often, the recommendations for the immunization of children with immune -mediated diseases follow the recommendations for immunocompromised patients. Vaccination against COVID-19, on the other hand, should ideally occur when the disease is stabilized and in the absence of a low degree of immunosuppression. The patients should be informed about the possibility that the immunization may fail during treatment with immunosuppressants. Specific vaccination schedules should be considered to ensure better protection.Conclusions: Recent studies have allowed updating the recommendations on the safety and immu-nogenicity of vaccination in children with immune-mediated diseases, especially for live attenu-ated vaccines. There is a scarcity of data on the safety and efficacy of COVID-19 vaccines in patients, particularly pediatric patients, with rheumatic diseases. The completion of ongoing stud-ies is expected to help guide recommendations on COVID-19 vaccines in this group of patients.(c) 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:S62 / S69
页数:8
相关论文
共 50 条
  • [41] Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
    Thierry Trenque
    Elise Lepoix
    Agathe Trenque
    Aurore Morel
    Brahim Azzouz
    European Journal of Clinical Pharmacology, 2022, 78 : 687 - 690
  • [42] Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
    Trenque, Thierry
    Lepoix, Elise
    Trenque, Agathe
    Morel, Aurore
    Azzouz, Brahim
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (04) : 687 - 690
  • [43] Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
    Edwards, Christopher J.
    Hercogova, Jana
    Albrand, Helene
    Amiot, Aurelian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1001 - 1014
  • [44] Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura
    Bae, Sung Hwa
    Kim, Sung-Hyun
    Bang, Soo-Mee
    BLOOD RESEARCH, 2022, 57 : 37 - 43
  • [45] Quality of Life Issues in Pediatric Immune-Mediated Inflammatory Disease
    Duffy, Ciaran M.
    Wells, George A.
    Russell, Anthony S.
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2011, 38 : 20 - 25
  • [46] The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases
    Odler, Balazs
    Tieu, Johanna
    Artinger, Katharina
    Chen-Xu, Michael
    Arnaud, Laurent
    Kitching, Richard A.
    Terrier, Benjamin
    Thiel, Jens
    Cid, Maria C.
    Rosenkranz, Alexander R.
    Kronbichler, Andreas
    Jayne, David R. W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, : II19 - II28
  • [47] Antibody-Mediated and Cellular Immune Responses Induced in Naive Volunteers by Vaccination with Long Synthetic Peptides Derived from the Plasmodium vivax Circumsporozoite Protein
    Arevalo-Herrera, Myriam
    Soto, Liliana
    Liliana Perlaza, Blanca
    Cespedes, Nora
    Vera, Omaira
    Milena Lenis, Ana
    Bonelo, Anilza
    Corradin, Giampietro
    Herrera, Socrates
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 84 (02): : 35 - 42
  • [48] COVID-19 Impact and Vaccination Willingness among Romanian Patients with Autoimmune/Immune-Mediated Diseases
    Pinte, Larisa
    Caraiola, Simona
    Balaban, Daniel Vasile
    Badea, Camelia
    Mazilu, Diana
    Ionescu, Georgeta Daniela
    Iosub, Maria-Ilinca
    Balan, Elena-Sabina
    Negoi, Florentina
    Dumitrescu, Bianca
    Mateescu, Bogdan
    Ionescu, Ruxandra
    Parvu, Magda Ileana
    Baicus, Cristian
    HEALTHCARE, 2021, 9 (12)
  • [49] Update on invasive meningococcal vaccination for Canadian children and youth
    Robinson, Joan L.
    PAEDIATRICS & CHILD HEALTH, 2018, 23 (01) : E1 - E4
  • [50] Immune response to hepatitis A vaccination in HIV-infected men in Greece
    Kourkounti, S.
    Mavrianou, N.
    Paparizos, Va
    Kyriakis, K.
    Hatzivassiliou, M.
    Kordosis, T.
    Katsambas, A.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (07) : 464 - 467